HITI
BEARISH
$2.33
Live
High Tide Inc. · NASDAQ
Target $5.67
(+143.2%)
$2.01
52W Range
$4.05
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 11, 2026
Market cap
$204.8M
P/E
N/A
ROE
-39.7%
Profit margin
-7.4%
Debt/Equity
1.1
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
HITI exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows strong top-line revenue growth of 25.20% and analysts maintain a 'strong_buy' rating with a target of $5.67, these are contradicted by a 0/100 technical trend and a negative profit margin of -7.42%. The disconnect between analyst optimism and the deterministic health scores suggests a high-risk speculative play rather than a value investment. The company's inability to convert revenue growth into consistent net income remains the primary concern.
Key Strengths
Strong YoY revenue growth of 25.20%
Positive operating margin of 2.32% suggesting core business viability
Very low Price/Sales ratio (0.33) indicating potential undervaluation of assets
Recent positive trend in EPS growth (+150% YoY)
Current ratio of 1.43 provides a basic liquidity cushion
Key Risks
Critical financial health (Piotroski F-Score 2/9)
Severe technical bearishness (Technical Trend 0/100)
Poor liquidity for immediate obligations (Quick Ratio 0.49)
Negative Return on Equity (-39.72%)
High historical volatility and consistent earnings misses
AI Fair Value Estimate
Based on comprehensive analysis
$3.15
+35.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
45
60
20
15
0
AI Verdict
Speculative/High Risk
Key drivers: Piotroski F-Score failure, Strong revenue growth, Bearish technicals, Negative net margins
Confidence
85%
Value
45/100
Trades at a low multiple of sales, but lacks the earnings to support a traditional value valuation.
Positives
- Low P/S ratio (0.33)
- Forward P/E of 16.47 is reasonable if earnings materialize
Watchpoints
- P/B of 3.23 is elevated for a company with negative ROE
- Lack of Graham Number due to negative earnings
Future
60/100
Growth is present in the top line, but bottom-line conversion is inconsistent.
Positives
- Consistent 25% revenue growth
- Improving EPS trajectory
Watchpoints
- Unreliable earnings track record
- High dependence on sector-specific regulatory shifts
Past
20/100
Long-term shareholders have seen significant capital erosion.
Positives
- 3Y change is positive (+84.9%)
Watchpoints
- 5Y change is devastating (-71.8%)
- Frequent earnings surprises to the downside
Health
15/100
Deterministic health scores indicate a company in a fragile financial state.
Positives
- Current ratio > 1.0
Watchpoints
- Piotroski F-Score 2/9 (Weak)
- Quick Ratio 0.49 (Low)
- Negative ROE
Dividend
0/100
Not a dividend-paying stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.33
Analyst Target
$5.67
Upside/Downside
+143.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HITI and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HITI
High Tide Inc.
Primary
|
-71.8% | +84.9% | +18.3% | -32.1% | -5.7% | +0.9% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
|
ADAG
Adagene Inc.
Peer
|
-81.2% | +188.8% | +109.6% | +84.4% | +33.2% | +45.4% |
|
ACB
Aurora Cannabis Inc.
Peer
|
-96.9% | -52.9% | -20.2% | -29.6% | -0.3% | -2.3% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
HIT
High Tide Inc.
Primary
5Y
-71.8%
3Y
+84.9%
1Y
+18.3%
6M
-32.1%
1M
-5.7%
1W
+0.9%
ANI
Anika Therapeutics, Inc.
Peer
5Y
-62.2%
3Y
-47.2%
1Y
-6.6%
6M
+63.8%
1M
+38.5%
1W
+0.6%
ADA
Adagene Inc.
Peer
5Y
-81.2%
3Y
+188.8%
1Y
+109.6%
6M
+84.4%
1M
+33.2%
1W
+45.4%
ACB
Aurora Cannabis Inc.
Peer
5Y
-96.9%
3Y
-52.9%
1Y
-20.2%
6M
-29.6%
1M
-0.3%
1W
-2.3%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
16.47
PEG Ratio
N/A
P/B Ratio
3.23
P/S Ratio
0.33
EV/Revenue
0.47
EV/EBITDA
10.1
Market Cap
$204.8M
Profitability
Profit margins and return metrics
Profit Margin
-7.42%
Operating Margin
2.32%
Gross Margin
25.8%
ROE
-39.72%
ROA
3.87%
Growth
Revenue and earnings growth rates
Revenue Growth
+25.2%
Earnings Growth
N/A
Q/Q Revenue Growth
+25.18%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.1
Moderate
Current Ratio
1.43
Good
Quick Ratio
0.49
Poor
Cash/Share
$0.42
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Revenue
$0.2B
Gross Margin
24.9%
Op. Margin
2.3%
Net Margin
0.7%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.1B
Debt/Equity
2.77x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
54%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-06-15
$N/A
2026-03-17
$0.01
+265.0% surprise
2026-01-29
$-0.41
-7232.8% surprise
2025-09-15
$0.01
+237.9% surprise
Healthcare Sector Comparison
Comparing HITI against 226 companies in the Healthcare sector
(19 bullish, 76 neutral, 131 bearish)
Return on Equity (ROE)
-39.72%
This Stock
vs
-40.43%
Sector Avg
-1.8%
(Below Avg)
Profit Margin
-7.42%
This Stock
vs
-18.65%
Sector Avg
-60.2%
(Weaker)
Debt to Equity
1.1
This Stock
vs
4.61
Sector Avg
-76.1%
(Less Debt)
Revenue Growth
25.2%
This Stock
vs
97.21%
Sector Avg
-74.1%
(Slower)
Current Ratio
1.43
This Stock
vs
3.51
Sector Avg
-59.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HITI
High Tide Inc.
|
BEARISH | $204.8M | - | -39.7% | -7.4% | $2.33 | |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | Compare |
|
ADAG
Adagene Inc.
|
BULLISH | $194.65M | - | -63.3% | -% | $4.13 | Compare |
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $194.51M | - | -15.5% | -22.5% | $3.43 | Compare |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
HITI
High Tide Inc.
BEARISH
Mkt Cap
$205M
P/E
-
ROE
-39.7%
Price
$2.33
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-30 | Kestenbaum (Menashe) | Director of Issuer | Acquisition in the public market at price 2.23 per | 4,489 | $10,010 |
| 2026-03-02 | Kestenbaum (Menashe) | Director of Issuer | Stock Award | - | - |
| 2026-02-19 | Sharma (Sandy) | Senior Officer of Issuer | Option Exercise | 8,447 | $11,487 |
| 2025-12-29 | Khan (Omar Yar) | Senior Officer of Issuer | Disposition in the public market at price 2.75 per | 225 | $618 |
| 2025-12-29 | Khan (Omar Yar) | Senior Officer of Issuer | Disposition in the public market at price 2.74 per | 3,100 | $8,490 |
| 2025-12-01 | Avzar (Joy) | Senior Officer of Issuer | Option Exercise | 7,654 | $19,854 |
| 2025-12-01 | Elliott (Andrea) | Director of Issuer | Option Exercise | 16,332 | $42,365 |
| 2025-12-01 | Grover (Harkirat) | Director of Issuer | Option Exercise | 71,608 | $185,751 |
| 2025-12-01 | Kaushal (Nitin) | Director of Issuer | Stock Award | 32,663 | - |
| 2025-12-01 | Khan (Omar Yar) | Senior Officer of Issuer | Option Exercise | 12,304 | $31,916 |
| 2025-12-01 | Khan (Omar Yar) | Senior Officer of Issuer | Option Exercise | 10,230 | $26,536 |
| 2025-12-01 | Kwan (Arthur) | Director of Issuer | Option Exercise | 32,663 | $84,727 |
| 2025-12-01 | Mahajan (Mayank) | Senior Officer of Issuer | Option Exercise | 17,109 | $44,380 |
| 2025-12-01 | Mahajan (Mayank) | Senior Officer of Issuer | Option Exercise | 7,113 | $18,451 |
| 2025-12-01 | Palalas (Andreas-Alexander) | Senior Officer of Issuer | Option Exercise | 11,947 | $30,990 |
Kestenbaum (Menashe)
Director of Issuer
2026-03-30
4,489 shares
·
$10,010
Kestenbaum (Menashe)
Director of Issuer
2026-03-02
Sharma (Sandy)
Senior Officer of Issuer
2026-02-19
8,447 shares
·
$11,487
Khan (Omar Yar)
Senior Officer of Issuer
2025-12-29
225 shares
·
$618
Khan (Omar Yar)
Senior Officer of Issuer
2025-12-29
3,100 shares
·
$8,490
Avzar (Joy)
Senior Officer of Issuer
2025-12-01
7,654 shares
·
$19,854
Elliott (Andrea)
Director of Issuer
2025-12-01
16,332 shares
·
$42,365
Grover (Harkirat)
Director of Issuer
2025-12-01
71,608 shares
·
$185,751
Kaushal (Nitin)
Director of Issuer
2025-12-01
32,663 shares
Khan (Omar Yar)
Senior Officer of Issuer
2025-12-01
12,304 shares
·
$31,916
Khan (Omar Yar)
Senior Officer of Issuer
2025-12-01
10,230 shares
·
$26,536
Kwan (Arthur)
Director of Issuer
2025-12-01
32,663 shares
·
$84,727
Mahajan (Mayank)
Senior Officer of Issuer
2025-12-01
17,109 shares
·
$44,380
Mahajan (Mayank)
Senior Officer of Issuer
2025-12-01
7,113 shares
·
$18,451
Palalas (Andreas-Alexander)
Senior Officer of Issuer
2025-12-01
11,947 shares
·
$30,990
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
3 analysts
Canaccord Genuity
2026-03-19
Buy
Buy
Past News Coverage
Recent headlines mentioning HITI from our newsroom.
Newest → oldest
No matching news yet.